Where does Exelixis, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Exelixis, Inc. ranks #5,513 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Exelixis, Inc. hold?

Exelixis, Inc. holds 62 US utility patents granted between 2015 and 2025, spanning 11 technology areas.

What is Exelixis, Inc.'s Innovation Score?

Exelixis, Inc. has an Innovation Score of 39.4 out of 100 (top 38% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Exelixis, Inc. focus on?

Exelixis, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 54 patents, ranking #326 of 6,058 assignees active in that subclass. Grants appear in 11 CPC subclasses total.

Is Exelixis, Inc.'s patent grant rate increasing or decreasing?

Exelixis, Inc.'s recent grant velocity is +71% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Exelixis, Inc.'s patents?

Exelixis, Inc.'s patents average 11.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Exelixis, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Exelixis, Inc.

USPTO PatentsView assignee record - 62 granted patents across 11 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Exelixis ranks #5,513 of 49,997 tracked US assignees by granted-patent volume, with 62 patents across 11 technology areas.

#5,513
of 49,997 US assignees by volume: Top 38%
by Innovation Score (39.4/100): 11.6
avg claims per patent: +71%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5513 · US Corporation #5,513 · 62 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 62 grants
UPPER-Q #5,513/49,997
PHOTO-FINISH Cleerly
CPC-FOCUS A61P · 11 areas
INNOV-THIN 39.4/100
CLAIMS-PAR 11.6 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +71% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cleerly, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Exelixis’s 39.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.3 pts (36%) Velocity 6.3 pts (16%) Breadth 11.7 pts (30%) Claim depth 7.0 pts (18%)

Qualcomm Incorporated · highest

85
Channel Medsystems · near

39
Exelixis · this assignee

39
Molo Design · near

39
Project Phoenix · near

39
uBiome · near

39
3D Lighting… · lowest

7

What this shows Exelixis's Innovation Score is 39.4/100 (top 38% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Exelixis?

Each dot is one of Exelixis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Exelixis’s own 11.6 claims/patent is at or below the 17.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Exelixis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Exelixis's grants concentrate

Exelixis, Inc. is a focused PatentsView assignee: 11 CPC subclasses with 87.1% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (10 grants) versus a trough of 1 in 2015. By volume, Exelixis sits between Cleerly, Inc. and Hytto PTE. Ltd..

Exelixis's three-year grant acceleration

From 2019–2021 to 2022–2024, Exelixis, Inc. moved from 21 to 20 grants (0.95x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Cleerly

62
Dspace

62
Egnyte

62
Evident

62
Goji

62
Groq

62
HMD Global Oy

62
Hytto PTE

62
Exelixis ◀

62

What this shows Exelixis holds 62 patents at rank #5,511, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Exelixis

By rank, the assignees closest to #5,511 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Exelixis's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Exelixis, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Exelixis ranks #326 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (39 here).

uBiome, Inc. 39 Channel Medsystems, Inc. 39 Project Phoenix, LLC 39 Molo Design, Ltd. 39

Similar claim depth

Nearest assignees by average claims per patent (11.6 here).

SnapRays, LLC 11.6 avg Johnson Controls, Inc. 11.6 avg Freni Brembo S.P.A. 11.6 avg Xencor, Inc. 11.6 avg

Exelixis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 38% higher than 62% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Exelixis, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	1.6%
2016	2	3.2%
2017	5	8.1%
2018	8	12.9%
2019	5	8.1%
2020	6	9.7%
2021	10	16.1%
2022	7	11.3%
2023	8	12.9%
2024	5	8.1%
2025partial year	5	8.1%

Which technologies does Exelixis, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 54

C07D - Heterocyclic Compounds 45

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 33

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 8

C07C - Acyclic OR Carbocyclic Compounds 5

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C07K - Peptides 3

Y02A - Technologies FOR Adaptation TO Climate Change 3

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

Top 11 of 11 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Exelixis, Inc.'s patent record in context - here's where to go next.

Exelixis, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 87.1% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #5,513 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Exelixis, Inc. against Cleerly, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.